Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Merus N.V. (NASDAQ: MRUS).

Full DD Report for MRUS

You must become a subscriber to view this report.


Recent News from (NASDAQ: MRUS)

Report: Developing Opportunities within Spotify Technology SA, Vornado Realty Trust, Merus N.V, Teekay Tankers, PagSeguro Digital, and Liberty Oilfield Services - Future Expectations, Projections Moving into 2018
NEW YORK, Oct. 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Spotify Technology SA (NYSE:SPOT), Vornado Realty Trust (NYSE:VNO), Me...
Source: GlobeNewswire
Date: October, 19 2018 09:20
Merus to Present at the Cantor Fitzgerald Global Healthcare Conference
UTRECHT, The Netherlands, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Hui Liu, Ph.D., Executive Vice President, Chief Business Officer and...
Source: GlobeNewswire
Date: September, 27 2018 16:00
Merus Strengthens Team with Key Appointments
Hui Liu, Ph.D., EVP, Chief Business Officer, appointed Head of Merus U.S. Peter B. Silverman, J.D., appointed EVP, General Counsel Jillian Connell joins as VP, Investor Relations and Corporate Communications UTRECHT, The Netherlands, Sept. 27, 2018 (GLOBE NEWSWIRE) --  Merus N.V. (...
Source: Thomson Reuters ONE
Date: September, 27 2018 07:00
Merus to Participate in Citi's 13th Annual Biotech Conference
UTRECHT, The Netherlands, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., President and Chief Executive Officer, will pa...
Source: GlobeNewswire
Date: August, 30 2018 07:00
Merus Announces Formation of a Scientific Advisory Board
- Key Oncology and Drug Development Professionals to Support Advancement of Merus’ Pipeline of Bispecific Antibodies - UTRECHT, The Netherlands, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific ant...
Source: Thomson Reuters ONE
Date: August, 22 2018 07:00
Recent Analysis Shows DURECT, Corporacion America Airports S.A., Golden Star Resources, MacroGenics, Merus N.V., and Superior Uniform Group Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of DURECT Corporation (NASDAQ:DRRX), Corporacion America Airports S.A. (NYSE...
Source: GlobeNewswire
Date: August, 21 2018 07:45
Merus revenues up 5%; net loss improves in Q2
Merus ( MRUS ) Q2 results (€): Revenues: 6.5M (+4.8%). More news on: Merus, Healthcare stocks news, Earnings news and commentary, Read more ...
Source: SeekingAlpha
Date: August, 10 2018 08:48
Merus Announces Financial Results for the Second Quarter 2018 & Mid-year Operating Results
MCLA-128 Phase 1/2 clinical data from the gastric cancer cohort will be presented at the European Society for Medical Oncology Congress in October 2018 UTRECHT, The Netherlands, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS) (“Merus”, “we”, “o...
Source: Thomson Reuters ONE
Date: August, 10 2018 08:35
Merus to Present at the 2018 Wedbush PacGrow Healthcare Conference
UTRECHT, The Netherlands, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Hui Liu, Ph.D., Executive Vice President and Chief Business Officer, wil...
Source: Thomson Reuters ONE
Date: August, 07 2018 07:00
Merus N.V. : Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018
- Initiation of Phase 1, first-in-human clinical trial of MCLA-158 in patients with solid tumors - - MCLA-128's unique mechanism of action published in the scientific journal Cancer Cell - UTRECHT, The Netherlands, July 26, 2018 (GLOBE NEWSWIRE) --  Merus N.V. (Nasdaq:MRUS) ("Mer...
Source: Thomson Reuters ONE
Date: July, 26 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0819.7019.2819.8919.00518,152
2018-05-1717.520717.8217.9717.5215,781
2018-02-2617.9017.9118.114317.8535,967
2018-02-2318.0617.9718.1017.9628,290
2018-02-2218.0117.9718.1417.9030,785

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-141,6432,50665.5626Short
2018-12-133,90410,10638.6305Short
2018-12-122,3785,10646.5727Short
2018-12-112,75818,02215.3035Cover
2018-12-1015,1250.0195Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MRUS.


About Merus N.V. (NASDAQ: MRUS)

Logo for Merus N.V. (NASDAQ: MRUS)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $330,113,118 - 05/11/2018
  • Issue and Outstanding: 19,429,848 - 12/31/2017

 


Recent Filings from (NASDAQ: MRUS)

Registration statement for certain foreign private issuers offered for certain transactions
Filing Type: F-3Filing Source: edgar
Filing Date: May, 15 2018
Annual and transition report of foreign private issuers under sections 13 or 15(d)
Filing Type: 20-FFiling Source: edgar
Filing Date: April, 30 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 05 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: February, 28 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 23 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 08 2018

 

 


Daily Technical Chart for (NASDAQ: MRUS)

Daily Technical Chart for (NASDAQ: MRUS)


Stay tuned for daily updates and more on (NASDAQ: MRUS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: MRUS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MRUS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MRUS and does not buy, sell, or trade any shares of MRUS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/